Premium
Biomarkers: improving the cost‐effectiveness of biological drugs for autoimmune disorders
Author(s) -
Gurwitz David
Publication year - 2011
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20464
Subject(s) - biological drugs , limiting , drug , pharmaceutical industry , attractiveness , risk analysis (engineering) , medicine , intensive care medicine , business , pharmacology , disease , psychology , engineering , mechanical engineering , psychoanalysis
Biological drugs are gradually becoming the treatment of choice for chronic autoimmune diseases. However, their high costs are a key healthcare concern limiting their attractiveness for payers. This can, in part, be offset by implementing drug response biomarkers so that payers will only cover the drugs for patients who are most likely to benefit from them. Identifying such biomarkers in turn depends on the availability of well‐characterized clinical samples. Research collaboration between the pharmaceutical industry, clinicians, and academia is paramount for achieving this goal. Drug Dev Res 72:549–552, 2011. © 2011 Wiley Periodicals, Inc.